PMID- 38189048
OWN - NLM
STAT- MEDLINE
DCOM- 20240109
LR  - 20240304
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a 
      Bayesian network meta-analysis.
PG  - 1282584
LID - 10.3389/fendo.2023.1282584 [doi]
LID - 1282584
AB  - BACKGROUND: As a popular antidiabetic drug, teneligliptin has been used for over 
      10 years, but its efficacy and safety have rarely been systematically evaluated. 
      Therefore, a Bayesian network meta-analysis was conducted to evaluate the 
      efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus 
      (T2DM). METHODS: We systematically searched PubMed, Web of Science, Embase, 
      Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. 
      Randomized controlled trials (RCTs) comparing teneligliptin with placebo or 
      active comparators in T2DM patients for at least 12 weeks were included in the 
      study. Data analysis was performed using R 4.2.3 and Stata 17.0 software. Each 
      outcome was presented as a mean difference (MD) or an odds ratio (OR) along with 
      95% confidence interval (CI) and the surface under the cumulative ranking curve 
      value (SUCRA). RESULTS: A total of 18 RCTs with 3,290 participants with T2DM were 
      included in this study. Generally, compared to placebo, sitagliptin, 
      vildagliptin, metformin, and bromocriptine, 20 mg of teneligliptin showed better 
      efficacy in reducing HbA1c (MD [95% CI], -0.78 [-0.86 to -0.70], -0.08 [-0.36 to 
      0.19], -0.04 [-0.72 to 0.60], -0.12 [-0.65 to 0.42], and -0.50 [-0.74 to -0.26], 
      respectively) and fasting plasma glucose (FPG) (MD [95% CI], -18.02 [-20.64 to 
      -15.13], 1.17 [-9.39 to 11.70], -8.06 [-30.95 to 14.35], -2.75 [-18.89 to 13.01], 
      and -34.23 [-45.93 to -22.96], respectively), and 40 mg of teneligliptin also 
      showed better efficacy in reducing HbA1c (MD [95% CI], -0.84 [-1.03 to -0.65], 
      -0.15 [-0.49 to 0.19], -0.10 [-0.81 to 0.57], -0.18 [-0.76 to 0.39], and -0.56 
      [-0.88 to -0.26], respectively) and FPG (MD [95% CI], -20.40 [-26.07 to -14.57], 
      -1.20 [-13.21 to 10.38], -10.43 [-34.16 to 12.65], -5.13 [-22.21 to 11.66], and 
      -36.61 [-49.33 to -24.01], respectively). Compared to placebo, 20 mg of 
      teneligliptin showed no significant difference in incidences of hypoglycemia and 
      gastrointestinal adverse events (OR [95% CI], 1.30 [0.70 to 2.19] and 1.48 [0.78 
      to 2.98], respectively), and 40 mg of teneligliptin showed no significant 
      difference in incidence of hypoglycemia (OR [95% CI], 2.63 [0.46 to 8.10]). 
      Generally, antidiabetic effect and hypoglycemia risk of teneligliptin gradually 
      increased as its dose increased from 5 mg to 40 mg. Compared to 20 mg of 
      teneligliptin, 40 mg of teneligliptin showed superior efficacy and no-inferior 
      safety, which was considered as the best option in reducing HbA1c, FPG, and 2h 
      PPG and increasing proportion of the patients achieving HbA1c < 7% (SUCRA, 
      85.51%, 84.24%, 79.06%, and 85.81%, respectively) among all the included 
      interventions. CONCLUSION: Compared to sitagliptin, vildagliptin, metformin, 
      bromocriptine, and placebo, teneligliptin displayed favorable efficacy and 
      acceptable safety in treating T2DM. Twenty milligrams or 40 mg per day was the 
      optimal dosage regimen of teneligliptin. The results of this study will provide 
      important evidence-based basis for rational use of teneligliptin and clinical 
      decision-making of T2DM medication.
CI  - Copyright (c) 2023 Zhu, Guan and Ma.
FAU - Zhu, Miao
AU  - Zhu M
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      China.
FAU - Guan, Ruifang
AU  - Guan R
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      China.
FAU - Ma, Guo
AU  - Ma G
AD  - Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20231218
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 
      (3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine)
RN  - 3A64E3G5ZO (Bromocriptine)
RN  - 0 (Glycated Hemoglobin)
RN  - I6B4B2U96P (Vildagliptin)
RN  - 9100L32L2N (Metformin)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - Bromocriptine
MH  - Glycated Hemoglobin
MH  - Network Meta-Analysis
MH  - Vildagliptin
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Metformin
MH  - Sitagliptin Phosphate
MH  - Hypoglycemic Agents/adverse effects
MH  - *Hypoglycemia
PMC - PMC10766708
OTO - NOTNLM
OT  - bayesian network meta-analysis
OT  - efficacy
OT  - safety
OT  - systematic review
OT  - teneligliptin
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/08 07:01
MHDA- 2024/01/09 06:42
PMCR- 2023/01/01
CRDT- 2024/01/08 05:29
PHST- 2023/08/26 00:00 [received]
PHST- 2023/11/09 00:00 [accepted]
PHST- 2024/01/09 06:42 [medline]
PHST- 2024/01/08 07:01 [pubmed]
PHST- 2024/01/08 05:29 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1282584 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Dec 18;14:1282584. doi: 
      10.3389/fendo.2023.1282584. eCollection 2023.